{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-100","upperLimit":"81.4","value":"-59.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"evaluate FDG-PET as a non-invasive functional imaging tool to assess in situ tumor metabolism (as measured by the Standardized Uptake Values of FDG in the tumor) prior to and during the administration of IM. %change in SUVmax \\<1 indicate decreased tumor metabolism while values \\>1 indicated an increase in tumor metabolism.\n\nMetabolic response by 18F-FDG PET was determined in accordance with the criteria of the European Organization for Research and Treatment of Cancer EORTC), with increases or decreases of more than 25% in SUVmax defining progressive metabolic disease (PMD) and partial metabolic response (PMR), respectively, and new lesions defining PMD.","dispersionType":"Full Range","groups":[{"description":"FDG-PET was done at baseline, 1-7 days after IM initiation, in patients with GIST undergoing neoadjuvant IM therapy.\n\nTumor GLUT4 expression by immunohistochemistry (IHC) and mutation analyses were done at baseline and/or surgery. Background-subtracted SUVmax was measured in all lesions and summed; Metabolic Response (MR)based on EORTC criteria was compared to Response Evaluation Criteria in Solid Tumors (RECIST), GLUT4 expression, and KIT/PDGFRA mutation status.","id":"OG000","title":"PET Patricipants"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"change from baseline to 1 week post therapy","title":"FDG-PET as Biological Marker of Metabolic Response(MR) During Imatinib Mesylate (IM) Treatment, in Patients With GIST Who Are naı¨ve to Tyrosine Kinase Inhibitor Therapy","type":"SECONDARY","unitOfMeasure":"percentage change in SUVmax"}